Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status.
|
|
|
- Corey Mitchell
- 5 years ago
- Views:
Transcription
1 Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status. R. Zalazar, M.D. Hernández, M. Páramo, P. Slon, M. Millor Muruzabal, J. Solorzano Rendon, M. Ribelles, J. Zubieta, M. Garcia de Eulate; Clínica Universidad de Navarra. Pamplona/ES
2 NIVERSITAS STVDIORV Introduction Glioblastoma multiforme is the most malignant type of glioma and has a very poor prognosis, having a mean survival of only 14 months
3 Patient A: 60 year old man, KPS 80 Patient B: 61 year old man, KPS 80
4 Patient A survival: 21 months Patient B survival: 6 months
5 NIVERSITAS STVDIORV Introduction Molecular Biomarkers MGMT EGFR ampl EGFRvIII Imaging Biomarkers Perfusion-MRI (rcbv) Diffusion-MRI (ADC) IDH 1/2 1p/19q PTEN p53
6 NIVERSITAS STVDIORV Introduction Molecular Biomarkers MGMT EGFR ampl EGFRvIII Imaging Biomarkers Perfusion-MRI (rcbv) Diffusion-MRI (ADC) IDH 1/2 1p/19q PTEN p53
7 NIVERSITAS STVDIORV Introduction Molecular Biomarkers MGMT EGFR ampl EGFRvIII Imaging Biomarkers Perfusion-MRI (rcbv) Diffusion-MRI (ADC) IDH 1/2 1p/19q PTEN p53
8 NIVERSITAS STVDIORV Objective To analyse whether apparent diffusion coefficient (ADC) values correlate with: SURVIVAL MGMT promoter methylation status in patients with glioblastoma multiforme (GBM).
9 NIVERSITAS STVDIORV Materials and Method Retrospective study: Oct 2007 Feb 2012 of 78 patients. Inclusion Criteria Newly diagnosed and untreated GBM Presurgical MRI At least 12 months follow-up or until their death This study was approved by the ethic committee at our institution
10 NIVERSITAS STVDIORV Materials and Method 78 patients with Newly diagnosed of GBM 21 patients were excluded 27 F 30 M 57 patients
11 MRI examination 4º SWI 1º DWI b1000 2º ADC 3º T1 + G
12 MRI examination 4º SWI 1º DWI b1000 2º 3º ADC T1 + G
13 MRI examination 4º SWI 1º DWI b1000 2º ADC 3º T1 + G
14 MRI examination 4º SWI 1º DWI b1000 2º ADC 3º T1 + G
15 MRI examination ROI 1 DWI b1000 ADC T1 + G
16 MRI examination ROI 2 T2 FLAIR ADC T1 + G
17 NIVERSITAS STVDIORV Materials and Method ADC index: ADC min SC / ADC mean NCWM
18 . Kaplan-Meier method. Cox regression model. ROC curves NIVERSITAS STVDIORV Materials and Method Clinical Molecular Surgical Imaging Age Sex MGMT status Pre-surgical volume Post-surgical volume ADCmin SC (solid component) Karnofsky Performance Score ADCindex: (ADC min SC/ADC mean N CWM) ADC index: ADC min SC / ADC mean NCWM Statistical analyses (SPSS 20.0)
19 NIVERSITAS STVDIORV Materials and Method Three groups were analysed N=19 1st group ADC-index > 0.7 MGMT-methylated-status Markers of GOOD prognosis N=10 2nd group ADC index < 0.7 MGMT non methylated status Markers of POOR prognosis N=53 3rd group MGMT-methylated status ADC index <0,7 (n=8) ADC index >0,7 (n=19) MGMT- non methylated status ADC index <0,7 (n=10) ADC index >0,7 (n=16)
20 NIVERSITAS STVDIORV Results PATIENT CHARACTERISTICS Age (years) Median (range) 60.5 (28-78) Sex Men 30 Women 27 KPS Median (range) 80 (40-100) Survival (months) Median (range) TUMOR CHARACTERISTICS MGMT Status n (%) Methylated 27/53 (50,94%) Unmethylated 26/53 (49,06%) Tumoral Volumen (cm 3 ) Mean ( SD) Presurgical 42,4 ( 26.7) Postsurgical 0,57(( 2,05) PFS 7,4 ( ) OS 17.8 ( )
21 NIVERSITAS STVDIORV Results PATIENT CHARACTERISTICS Age (years) Median (range) 60.5 (28-78) Sex Men 30 Women 27 TUMOR CHARACTERISTICS MGMT Status n (%) Methylated 27/53 (50,94%) Meythylated 50,94%% Unmethylated 26/53 (49,06%) KPS Median (range) 80 (40-100) Survival (months) Median (range) PFS 7,4 ( ) OS 17.8 ( )
22 NIVERSITAS STVDIORV Results PATIENT CHARACTERISTICS Age (years) Median (range) 60.5 (28-78) Sex TUMOR CHARACTERISTICS MGMT Status n (%) Men 30 Women 27 KPS Median (range) 80 (40-100) Survival (months) Median (range) Tumoral Volumen (cm 3 ) Mean ( SD) Presurgical 42,4 ( 26.7) Post-surgical 0,57cm 3 Postsurgical 0,57(( 2,05) PFS 7,4 ( ) OS 17.8 ( )
23 NIVERSITAS STVDIORV Results ADC values according to MGMT status ADCmin Solid Component p=ns ADC index Methylated Non methylated Methylated Non methylated AUC: 0,55
24 NIVERSITAS STVDIORV Results Univariate analysis PFS OS HR (95% CI) p value HR (95% CI) p value Age 1,00 (0,98-1,03) NS 1,04 (1,0-1,07) 0,01 Sex 0,75 (0,41-1,36) NS 1,2 (0,7-2,3) NS KPS 0,99 (0,97-1,14) NS 0,98 (0,96-1,00) 0.06 MGMT 2,96 (1,5-5,7) 0,001 1,62 (0,84-3,1) 0,14 Presurgical Volumen 1,0 (0,99-1,0) NS 1,0 (0,99-1,01) NS Postsurgical Volumen 0,97 (0,82-1,14) NS 0,94 (0, ) NS ADCmin Solid Component 0,31(0,32-3,13) NS 0,01 (0,01-0,14) <0,001 ADCindex 0,72 (0,23-2,2) NS 0,05 (0,07-0,35) =0,003
25 NIVERSITAS STVDIORV Results Univariate analysis PFS OS HR (95% CI) p value HR (95% CI) p value Age 1,00 (0,98-1,03) NS 1,04 (1,0-1,07) 0,01 Sex 0,75 (0,41-1,36) NS 1,2 (0,7-2,3) NS KPS 0,99 (0,97-1,14) NS 0,98 (0,96-1,00) 0.06 MGMT p<0,001 p=ns% MGMT 2,96 (1,5-5,7) 0,001 1,62 (0,84-3,1) 0,14 Presurgical Volumen 1,0 (0,99-1,0) NS 1,0 (0,99-1,01) NS Postsurgical Volumen 0,97 (0,82-1,14) NS 0,94 (0, ) NS ADCmin Solid Component 0,31(0,32-3,13) NS 0,01 (0,01-0,14) <0,001 ADCindex 0,72 (0,23-2,2) NS 0,05 (0,07-0,35) =0,003
26 NIVERSITAS STVDIORV Results Univariate analysis PFS OS HR (95% CI) p value HR (95% CI) p value Age 1,00 (0,98-1,03) NS 1,04 (1,0-1,07) 0,01 Sex 0,75 (0,41-1,36) NS 1,2 (0,7-2,3) NS KPS 0,99 (0,97-1,14) NS 0,98 (0,96-1,00) 0.06 MGMT 2,96 (1,5-5,7) 0,001 1,62 (0,84-3,1) 0,14 Presurgical Volumen 1,0 (0,99-1,0) NS 1,0 (0,99-1,01) NS Postsurgical Volumen 0,97 (0,82-1,14) NS 0,94 (0, ) NS ADCmin Solid Component 0,31(0,32-3,13) NS 0,01 (0,01-0,14) <0,001 ADCindex 0,72 (0,23-2,2) NS 0,05 (0,07-0,35) =0,003
27 NIVERSITAS STVDIORV Results Univariate analysis PFS OS HR (95% CI) p value HR (95% CI) p value Age 1,00 (0,98-1,03) NS 1,04 (1,0-1,07) 0,01 Age p=ns =0,01% Sex 0,75 (0,41-1,36) NS 1,2 (0,7-2,3) NS KPS MGMT Presurgical Volumen Postsurgical Volumen ADCmin Solid Component ADCmin SC p=ns <0,001 ADCindex p=ns =0,003 0,31(0,32-3,13) NS 0,01 (0,01-0,14) <0,001 ADCindex 0,72 (0,23-2,2) NS 0,05 (0,07-0,35) =0,003
28 NIVERSITAS STVDIORV Results Multivariate analysis PFS OS HR (95% CI) p value HR (95% CI) p value MGMT 3,2 (1,6-6,7) 0,001 2,1 (1,04-4,2) 0,037 ADCmin Solid Component 0,40 (0,02-7,7) 0,54 0,003 (0,0-0,08) 0,001 * Adjusted for age, sex and KPS
29 NIVERSITAS STVDIORV Results Multivariate analysis PFS OS HR (95% CI) p value HR (95% CI) p value MGMT 3,2 (1,6-6,7) 0,001 2,1 (1,04-4,2) 0,037 ADCmin Solid Component 0,40 (0,02-7,7) 0,54 0,003 (0,0-0,08) 0,001 * Adjusted for age, sex and KPS
30 NIVERSITAS STVDIORV Results MGMT Status Progression-Free Survival Overall Survival p=0,002 p=ns Methylated status Methylated status Non methylated status Non methylated status MGMT-status correlated better with PFS (p=0,002)
31 NIVERSITAS STVDIORV Results ADC-min SC Progression-Free Survival Overall Survival <0,63 >0,63 p = 0.06 > 0.63 < 0.63 <0,63 >0,63 p=0,001 ADC-min SC correlate better with OS (p=0,001)
32 NIVERSITAS STVDIORV Results ADC-index Progression-Free Survival Overall Survival <0,7 >0,7 p = 0.02 <0,7 >0,7 p=0,001 ADC-index correlate better with OS (p=0,001)
33 NIVERSITAS STVDIORV Results Group 1 p =0,014 vs Group 2 Group 1 PROGRESSION FREE SURVIVAL Group 2 months ( months )
34 NIVERSITAS STVDIORV Results Group 1 p =0,001 vs Group 2 Group 1 OVERALL SURVIVAL Group 2 ( months )
35 NIVERSITAS STVDIORV Results OVERALL SURVIVAL MGMT-methylated ADCindex >0,7 MGMT-methylated status ADC index <0,7 ADC index >0,7 p=0,001 ADCindex <0,7 OVERALL SURVIVAL months
36 NIVERSITAS STVDIORV Results OVERALL SURVIVAL MGMT-methylated ADCindex >0,7 MGMT-methylated status ADC index <0,7 ADC index >0,7 p=0,001 ADCindex <0,7 OVERALL SURVIVAL months
37 NIVERSITAS STVDIORV Results OVERALL SURVIVAL MGMT- non methylated ADC index >0,7 MGMT- non methylated status ADC index <0,7 ADC index >0,7 p=0,027 OVERALL SURVIVAL ADCindex <0,7 months
38 NIVERSITAS STVDIORV Results OVERALL SURVIVAL MGMT- non methylated ADC index >0,7 MGMT- non methylated status ADC index <0,7 ADC index >0,7 p=0,027 OVERALL SURVIVAL ADCindex <0,7 months
39 NIVERSITAS STVDIORV Conclusions 1 ADCmin value of the SC of the tumor and the ADCindex value correlated significantly with overall survival, independently of the MGMT status.
40 NIVERSITAS STVDIORV Conclusions 1 ADCmin value of the SC of the tumor and the ADCíndex value correlated significantly with overall survival, independently of the MGMT status. 2 There were no significant differences in the values of ADC in the patients with MGMT methylation and MGMT non methylation status.
41 NIVERSITAS STVDIORV Conclusions Our findings suggest that ADC values are not useful to predict the MGMT status.. But it is strong independent predictors of survival in those patients
42 Laura Romina Zalazar
To analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma
To analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma R. Zalazar, M. Páramo, M. Hernández, P. Domínguez, J.Etxano, P.García Barquín, H.Quiceno Arias,
Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme
Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme Adil Bata 1, Jai Shankar 2 1 Faculty of Medicine, Class of 2017 2 Department of Diagnostic Radiology, Division of Neuroradiology,
Accepted: 13 June 2018
Received: 26 February 2018 Revised: 12 June 2018 DOI: 10.1002/cam4.1666 Accepted: 13 June 2018 ORIGINAL RESEARCH The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized
Concepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015
Concepts for a personalized neurosurgical oncology Jörg-Christian Tonn Dept. of Neurosurgery Ludwig-Maximilian University München Großhadern Germany XXIV Annual Conference Pietro Paoletti 27. November
MRS and Perfusion of Brain Tumors
Department of Radiology University of California San Diego MRS and Perfusion of Brain Tumors John R. Hesselink, M.D. MRS & Perfusion of Brain Tumors Tumor histology Degree of malignancy Delineate tumor
Early postoperative tumor progression predicts clinical outcome in glioblastoma implication for clinical trials
J Neurooncol (2017) 132:249 254 DOI 10.1007/s11060-016-2362-z CLINICAL STUDY Early postoperative tumor progression predicts clinical outcome in glioblastoma implication for clinical trials Andreas Merkel
MR-Radiomics in Neuro-Oncology
Klinik für Stereotaxie und funktionelle Neurochirurgie Institut für Neurowissenschaften und Medizin MR-Radiomics in Neuro-Oncology M. Kocher Klinik für funktionelle Neurochirurgie und Stereotaxie Forschungszentrum
Prediction of 1p/19q status promotes a more effective personalized therapy and help stratify patients in clincial trials
VSNR51 Neuroradiology Series: Brain Tumors Series Courses OI NM MI BQ NR AMA PRA Category 1 Credits : 3.25 ARRT Category A+ Credits: 3.75 Thu, Dec 4 8:30 AM - 12:00 PM Location: N228 Participants Moderator
A clinical perspective on neuropathology and molecular genetics in brain tumors
A clinical perspective on neuropathology and molecular genetics in brain tumors M.J. van den Bent Erasmus MC Cancer Institute Rotterdam, the Netherlands Disclosures Member speakersbureau: MSD Consultancy:
Development and ini.al valida.on of a prognos.c nomogram for ambulatory pa.ents with advanced cancer
Session: What Does the Future Hold? Prognos7ca7on in Advanced Cancer and Clinical Decision Making Development and ini.al valida.on of a prognos.c nomogram for ambulatory pa.ents with advanced cancer Paiva
Supplementary Material
Supplementary Material Identification of mir-187 and mir-182 as biomarkers for early diagnosis and prognosis in prostate cancer patients treated with radical prostatectomy Irene Casanova-Salas 1, José
Characterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
MOLECULAR DIAGNOSTICS OF GLIOMAS
MOLECULAR DIAGNOSTICS OF GLIOMAS Arie Perry, M.D. Director, Neuropathology Division DIFFUSE GLIOMAS Cell types Astrocytomas (A) Oligodendrogliomas (O) Mixed oligoastrocytoma (MOA) Three WHO grades: II,
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bredel M, Scholtens DM, Yadav AK, et al. NFKBIA deletion in
Computer-extracted MR imaging features are associated with survival in glioblastoma patients
Computer-extracted MR imaging features are associated with survival in glioblastoma patients Maciej A. Mazurowski, Ph.D. 1, Jing Zhang, Ph.D. 1, Katherine B. Peters, M.D., Ph.D. 2, Hasan Hobbs, M.D. 1
2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
Institute of Oncology & Radiobiology. Havana, Cuba. INOR
Institute of Oncology & Radiobiology. Havana, Cuba. INOR 1 Transition from 2-D 2 D to 3-D 3 D conformal radiotherapy in high grade gliomas: : our experience in Cuba Chon. I, MD - Chi. D, MD - Alert.J,
Precision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
Radioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES
DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro THE STANDARD OF CARE
Asma Bashir, MD, 1 Jannick Brennum, MD, DMSc, 2 Helle Broholm, MD, 3 and Ian Law, MD, PhD, DMSc 1
CLINICAL ARTICLE The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[ 18 F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study Asma Bashir,
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA
RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA MULTIFORM GEINO 2014 Dra Estela Pineda Madrid Hospital Clínic Barcelona EGFRvIII in glioblastoma multiform The most common mutation of EGFR in GBM Expressed in 30%
Immuno-Oncology. Glioblastoma and CNS tumors 5 July 2016 Siena, Italy
ESMO Preceptorship Programme Immuno-Oncology From the essentials of tumour immunology to clinical application Glioblastoma and CNS tumors 5 July 2016 Siena, Italy Michael Weller Department of Neurology
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
CHAP 11 Contrast Enhanced MRI - Perfusion. CHAP 11 Contrast Enhanced MRI - Perfusion
CHAP 11 Contrast Enhanced MRI - Perfusion Contrast agents Paramagnetic / superparamagnetic Relaxivity Water exchange Susceptibility effect Brain perfusion pathologies Perfusion measurement T2* (DSC-MRI)
Magnetic Resonance Imaging for Prediction and Assessment of Treatment Response in Bevacizumab-Treated Recurrent Glioblastoma
Magnetic Resonance Imaging for Prediction and Assessment of Treatment Response in Bevacizumab-Treated Recurrent Glioblastoma The Harvard community has made this article openly available. Please share how
Marizomib (MRZ): Brain Penetrant Irreversible Pan-Proteasome Inhibitor
MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY Daniela Bota, MD, PhD 1, Annick Desjardins, MD,
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
Redgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
Clinical significance of FBXO17 gene expression in high-grade glioma
Du et al. BMC Cancer (2018) 18:773 https://doi.org/10.1186/s12885-018-4680-3 RESEARCH ARTICLE Open Access Clinical significance of FBXO17 gene expression in high-grade glioma Di Du 1, Jian Yuan 2, Wencai
Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 19 CH-857 Zurich http://www.zora.uzh.ch Year: 29 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
Contemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
Is there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma?
Is there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma? Juan M Sepúlveda Sánchez Neurooncology Unit Hospital Universitario 12 de Octubre. Madrid Topics 1.-EGFR pathway as a potential
Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.
Translating MRS into clinical benefit for children with brain tumours
Translating MRS into clinical benefit for children with brain tumours Andrew Peet NIHR Research Professor Childhood Cancer The Facts Cancer is the most common cause of death from disease in childhood Brain
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
Glioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
The New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas
The New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas Stefan Prokop, MD Neuropathology Fellow Hospital of the University of Pennsylvania Background
Related Policies None
Medical Policy MP 2.04.113 BCBSA Ref. Policy: 2.04.113 Last Review: 05/30/2018 Effective Date: 05/30/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,
Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma 1
This copy is for personal use only. To order printed copies, contact reprints@rsna.org Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing
DOI.7/s4--3-7 ORIGINAL ARTICLE Detection of IDH mutation in human gliomas: comparison of immunohistochemistry and sequencing Shingo Takano Wei Tian Masahide Matsuda Tetsuya Yamamoto Eiichi Ishikawa Mika
gliomas. Fetal brain expected who each low-
Supplementary Figure S1. Grade-specificity aberrant expression of HOXA genes in gliomas. (A) Representative RT-PCR analyses of HOXA gene expression in human astrocytomas. Exemplified glioma samples include
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
High Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.24.10621 RESEARCH ARTICLE High Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas Yao-Wu Wang 1, Chun-Li Yin 2, Hong-Yi Zhang
Arbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia
THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical
Predictive Biomarkers in GBM
Predictive Biomarkers in GBM C. David James, Ph.D. Professor & Associate Director, Brain Tumor Research Center Dept. Neurological Surgery and Helen Diller Comprehensive Cancer Center, University of California
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
Antiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /
Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases
MEETING SUMMARY ASH 2018, San Diego, USA
MEETING SUMMARY ASH 2018, San Diego, USA Prof. Stefano Luminari University of Modena and Reggio Emilia, Italy AN UPDATE ON PROGNOSTIC FACTORS IN INDOLENT LYMPHOMAS 2 DISCLAIMER Please note: The views expressed
Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma
Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Correlation With MGMT Promoter Methylation Status Alba A. Brandes, MD 1 ; Enrico Franceschi, MD 1 ; Alicia Tosoni,
Corporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION *
CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION * Alessandro Olivi, MD, Jaishri Blakeley, MD, and Allen K. Sills, MD, FACS ABSTRACT The management of glioma
Biomarkers in the Assessment of Congestive Heart Failure
Biomarkers in the Assessment of Congestive Heart Failure Mid-Regional pro-adrenomedullin (MR-proADM) vs BNP & NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial
Clinical Trials for Adult Brain Tumors - the Imaging Perspective
Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
Supplementary Online Content
Supplementary Online Content Bell EH, Pugh SL, McElroy JP, et al. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG Oncology
Prognostic value of baseline MRI in Glioblastoma Multiforme patients: a survival analysis of morphological, volumetric and diffusion MRI predictors
Prognostic value of baseline MRI in Glioblastoma Multiforme patients: a survival analysis of morphological, volumetric and diffusion MRI predictors Poster No.: C-1179 Congress: ECR 2016 Type: Authors:
Circulating microrna-137 is a potential biomarker for human glioblastoma
European Review for Medical and Pharmacological Sciences Circulating microrna-137 is a potential biomarker for human glioblastoma H.-Y. LI, Y.-M. LI, Y. LI, X.-W. SHI, H. CHEN 2016; 20: 3599-3604 Department
Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
Interferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas
MOLECULAR AND CLINICAL ONCOLOGY 3: 909-913, 2015 Interferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas HIROSHI KAWAJI, TSUTOMU TOKUYAMA, TOMOHIRO YAMASAKI,
2011 Oncology Highlights News from ASCO 2011:
2011 Oncology Highlights News from ASCO 2011: Malignant Glioma David A. Reardon, M.D. Clinical Director Center for Neuro-Oncology Dana-Farber Cancer Institute 450 Brookline Avenue SW-430 Boston, MA 02215
Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment
Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Jennifer Wright Neurosurgery SSC Audit Team Jennifer Wright, Rachel Tresman, Cyril Dubois, Surash Surash,
M. Kalousová, H. Benáková, A. A. Kuběna, S. Dusilová-Sulková, V. Tesař, T. Zima
Pregnancy-associated associated plasma protein-a (PAPP-A) A) as a mortality predictor of long-term hemodialysis patients M. Kalousová, H. Benáková, A. A. Kuběna, S. Dusilová-Sulková, V. Tesař, T. Zima
CNS SESSION 3/8/ th Multidisciplinary Management of Cancers: A Case based Approach
CNS SESSION Chair: Ruben Fragoso, MD/PhD UC Davis Fellow: Michael Cardenas, MD UC Davis Panel: Gordon Li, MD Stanford Seema Nagpal, MD Stanford Jennie Taylor, MD UCSF HPI: 46 yo right handed woman who
GEINO TRIALS. RESULTS IN 2015
VII Symposium Educacional GEINO Madrid, 3-4 diciembre 2015 GEINO TRIALS. RESULTS IN 2015 Juan M Sepúlveda Sánchez Unidad Multidisciplinar de Neurooncología Hospital 12 de Octubre GEINO-11: A Prospective
Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
Goals for this Lecture. Case 1. Key Points MRI TECHNIQUES FOR DIFFERENTIAL DIAGNOSIS OF RECURRENT BRAIN LESIONS
MRI TECHNIQUES FOR DIFFERENTIAL DIAGNOSIS OF RECURRENT BRAIN LESIONS Goals for this Lecture 1. Review common appearances for recurrent tumor and treatment effects on conventional MRI 2. Discuss current
Glioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis
Author's response to reviews Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis Authors: Mei-Yin Zhang (zhangmy@sysucc.org.cn) Shu-Hong
See the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, An extent of resection threshold for newly diagnosed glioblastomas
See the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, 2011 An extent of resection threshold for newly diagnosed glioblastomas Clinical article Nader Sanai, M.D., 1 Mei-Yin Polley,
Correlation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
Glioblastoma: Current Treatment Approach 8/20/2018
Glioblastoma: Current Treatment Approach 8/20/2018 Overview What is Glioblastoma? How is it diagnosed How is it treated? Principles of Treatment Surgery, Radiation, Chemotherapy Current Standard of care
Imaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
Protocol Abstract and Schema
Protocol Abstract and Schema This is a phase I/II study to determine: 1) the maximum tolerated dose (MTD) or recommended phase II dose of ABT-888 in combination with radiation therapy, and 2) the efficacy
Challenges on Assessment of Treatment Response for Physiologically Adaptive Radiation Therapy
Challenges on Assessment of Treatment Response for Physiologically Adaptive Radiation Therapy Yue Cao, Ph.D. Departments of Radiation Oncology, Radiology and Biomedical Engineering University of Michigan
High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
Glioblastomas (GBMs) are the most deadly primary tumors in
Published December 26, 2014 as 10.3174/ajnr.A4196 ORIGINAL RESEARCH BRAIN Arterial Spin-Labeling Perfusion MRI Stratifies Progression-Free Survival and Correlates with Epidermal Growth Factor Receptor
Glioblastoma Multiforme
Glioblastoma Multiforme Highly malignant, invasive, difficult-to-treat primary brain tumor" " Frequency: 9,000 cases/year (peak age, 55 65 years)" " Recurrence: rapid growth; size may double every 10 days"
TÍTULO The role of FUSION between MRI and PET-CT as preoperative staging in breast cancer
TÍTULO The role of FUSION between MRI and PET-CT as preoperative staging in breast cancer Páramo M, Zalazar R, Elizalde A, Pina-Insausti L, Vigil C, Hernández M, Rodríguez-Fraile M Clínica Universidad
Lymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
Case Presentation: USCAP Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center
Case Presentation: USCAP 2016 Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center Case History 53 year old female with a long standing history of migraines
Immuno-Oncology. Glioblastoma 3 November 2016 Zurich, Switzerland
ESMO Preceptorship Programme Immuno-Oncology From the essentials of tumour immunology to clinical application Glioblastoma 3 November 2016 Zurich, Switzerland Michael Weller Department of Neurology & Brain
Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme
Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme Adam J. Kole, MD, PhD 1 ; Henry S. Park, MD, MPH 1 ; Debra N. Yeboa, MD 1 ; Charles E. Rutter, MD 1 ; Christopher
Hyponatremia in small cell lung cancer is associated with a poorer prognosis
Original Article Hyponatremia in small cell lung cancer is associated with a poorer prognosis Wenxian Wang 1, Zhengbo Song 1,2, Yiping Zhang 1,2 1 Department of Chemotherapy, Zhejiang Cancer Hospital,
Supplementary Information
Supplementary Information Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma Tomohiro Yamaki, Yusuke Suenaga, Toshihiko Iuchi, Jennifer Alagu, Atsushi Takatori,
Management of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS
Management of Glioma: The Basics Glioma Update 3 oger Stupp, MD Department of Oncology & Cancer Center University Hospital Zurich, Switzerland (roger.stupp@usz.ch) Bern, 3. August 3 The clinical challenge
University of Alberta. Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers
University of Alberta Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers by Ibrahim Alnaami A thesis submitted to the Faculty of
A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors
DOI 10.1007/s11060-012-1026-x CLINICAL STUDY A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors Haihui Jiang Xiaohui Ren Wei Zhang Jun Ma Dali
21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology